The PRP vs PRF question is usually asked as though it were a question about brands, kits or marketing. It is not. It is a question about one decision made in the first three seconds of the blood draw — whether an anticoagulant enters the tube — and about everything that decision forces downstream. Same patient, same vein, same centrifuge, two materials that behave so differently in your hand and in the tissue that they are better understood as separate products than as two grades of the same one.
This piece is the descriptive half of the question: what the two materials are, why they differ, and what the measured release data actually show. It deliberately does not tell you which to pick for a given face. That is a separate discipline, and it belongs in its own document.
One draw, two materials: where the paths separate
Both PRP and PRF begin identically. Peripheral venous blood, drawn from the patient you are about to treat, spun in a centrifuge, and returned to that same patient. Both are autologous throughout. Neither has a foreign biomaterial added to it. In the language of the field, both are autologous platelet concentrates — the umbrella term that covers the whole family.
The divergence happens at the tube.
A PRP tube contains an anticoagulant, almost always sodium citrate or acid-citrate-dextrose (ACD-A). A PRF tube contains nothing. It is a plain or silica-coated tube with no additive at all, and that absence is the entire design.
Everything else — the viscosity in the syringe, the instrument you deliver it through, how long you have before it is unusable, how quickly it releases its growth factors, and what the tissue sees on day seven — descends from that single choice.
The anticoagulant decision is the whole fork in the road
Citrate and ACD-A work by chelating ionised calcium. Calcium is a required cofactor at multiple steps of the coagulation cascade; strip it out of the sample and the cascade stalls before thrombin can be generated in any meaningful quantity. No thrombin means no conversion of soluble fibrinogen into insoluble fibrin. The plasma stays plasma.
That is why PRP is liquid, and why it stays liquid. It is not that PRP is "less concentrated" or "weaker" — it is that the scaffold-building step has been chemically prevented. The platelets are suspended, mobile, and available to release on contact with tissue collagen or on deliberate activation with calcium chloride.
The choice of chelator is not neutral either. A 2026 prospective paired study comparing K2-EDTA with 3.2% sodium citrate in the same patients found that EDTA produced systematically inflated platelet morphology indices — mean platelet volume higher by 10.1%, large platelet ratio by 25.8% — in every one of 26 paired samples, consistent with chelation-induced swelling rather than any real change in the platelets themselves (García-Bordes et al., Biomedicines, 2026). Total platelet count did not differ. The practical consequence for anyone reading a kit's yield claims: the anticoagulant used to generate the number changes the number.
Remove the anticoagulant entirely, and the opposite process runs. From the instant blood contacts the tube wall, contact activation begins, thrombin is generated, and fibrinogen starts polymerising into a three-dimensional fibrin mesh. The centrifuge is racing that reaction. You are not preventing a clot; you are spinning a sample that is already becoming one, and harvesting it at the moment it is still liquid enough to draw up but already committed to gelling.
That is the material difference in one sentence. PRP is a suspension. PRF is a scaffold caught mid-formation.
What the centrifuge is actually sorting
Relative centrifugal force separates by density: red cells to the bottom, a buffy coat layer containing leukocytes and the bulk of the platelets in the middle, and plasma above. Both preparations exploit the same physics. What differs is the force applied and what that force does to a sample that is simultaneously trying to clot.
PRF protocols are characteristically low speed. The original injectable PRF description used roughly 700 rpm for a short spin; contemporary protocols cluster around 700 RCF for 8 minutes for concentrated variants. The rationale is that lower force leaves more platelets and leukocytes distributed in the upper layer rather than pelleting them downward, and produces a more porous, less stratified fibrin architecture.
This has been demonstrated directly. A 2026 study using fibrinolytic digestion and flow cytometry to count cells inside PRF matrices found that high-speed protocols produced pronounced cellular stratification and denser fibrin networks, while low-speed protocols gave a more homogeneous leukocyte distribution inside a porous mesh (Apaiso et al., Biomedicines, 2026). Denser is not automatically better. A tight mesh releases more slowly and resists degradation longer; an open mesh permits more cell migration into it. Those are different clinical properties, not a ranking.
The tube surface matters as much as the speed, and this is the variable most clinics never audit. Silica-coated plastic tubes spun at 2000 g for 3 minutes produced injectable PRF with roughly ten times the fibrin density and a three-fold faster solidification time than non-coated plain plastic tubes spun at 700 g for 8 minutes (Jagdish et al., Contemporary Clinical Dentistry, 2025). Silica is a contact activator. Coating the inside of the tube accelerates the very reaction you are trying to outrun.
If two clinicians say "I use PRF" and one is buying silica-coated tubes and the other plain plastic, they are handling two materials with materially different working windows.
Liquid plasma versus a fibrin scaffold: what the tissue receives
Injected PRP arrives as a fluid bolus of concentrated platelets in plasma. It distributes along tissue planes, follows the path of least resistance, and is cleared on the tissue's own schedule. Platelets degranulate on contact and on activation, and the alpha-granule contents — PDGF isoforms, TGF-β1, VEGF, EGF, IGF — enter the local environment essentially all at once.
Injected PRF arrives as a fluid that becomes a solid in situ. Within minutes the fibrin polymerises around the platelets and leukocytes it carried, producing a physical mesh embedded in the tissue. That mesh does three things a liquid cannot. It physically occupies space, briefly. It holds cells in place rather than letting them disperse. And it releases its growth factor cargo as the mesh itself slowly degrades, which takes days rather than hours.
This is the mechanism behind every clinical claim made for PRF's "sustained release." The sustained release is not a property of the platelets. It is a property of the cage they are trapped in.
Release kinetics: what the measurements show
The foundational comparison is Kobayashi and colleagues, published in Clinical Oral Investigations in 2016. Eighteen samples from six donors were prepared as PRP, PRF or advanced-PRF and assayed by ELISA for PDGF-AA, PDGF-AB, PDGF-BB, TGF-β1, VEGF, EGF and IGF at six time points: 15 minutes, 60 minutes, 8 hours, 1 day, 3 days and 10 days.
The results are unambiguous in shape:
- At 15 and 60 minutes, PRP released significantly more growth factor than either PRF preparation.
- At later time points out to 10 days, A-PRF routinely released the highest totals.
- Over the full 10-day accumulation, A-PRF released significantly more total protein than PRP or conventional PRF.
The authors' own conclusion is the cleanest summary available: PRP is recommended for fast delivery of growth factors; A-PRF is better suited to long-term release.
A 2025 systematic review across all fields of medicine reached the same conclusion from 23 included studies, finding that injectable PRF yielded higher platelet concentrations and more sustained long-term growth factor release than PRP, with 72% of studies favouring i-PRF on outcome and 24% finding no difference (Farshidfar et al., Periodontology 2000, 2025). The same review noted that where PRP won, it won on short-term effect — a pattern entirely consistent with a front-loaded release curve.
Two curves, not two potencies
The single most common misreading of this data is that PRF is "stronger." It is not. It is slower. The total signal delivered is broadly comparable; the shape of the delivery differs.
Picture two curves on the same axes. PRP is a spike: steep rise, high peak inside the first hour, decaying through the first day. PRF is a plateau: lower peak, but still measurably releasing at day 3 and day 10.
Which curve you want is an indication question, not a quality question.
How Tatiana Sarmiento frames the difference chairside
In Empire Medical Training's curriculum, Tatiana Sarmiento teaches this distinction in the compressed form a clinician can actually hold during a consultation: PRP is a fast signal; PRF is a sustained signal held in a fibrin support. PRP's release is largely spent within roughly the first 24 hours. PRF continues releasing across roughly 72 hours and beyond. When she reaches for PRF in a given case, it is specifically because she wants a longer release of growth factor into that tissue.
She is also precise about what that does not mean. PRP absolutely does release growth factors, and releases more of them, sooner, than PRF does. What PRP does not do is keep releasing. If your clinical goal requires signal still present in the tissue on day three, a front-loaded product is the wrong tool — not because it is inert, but because it has already finished.
These figures reflect Tatiana Sarmiento's clinical practice as taught in Empire Medical Training's hands-on curriculum. Technique is learned under supervision; this article is educational and is not a substitute for training.
The classification problem nobody mentions
"PRP" and "PRF" are not two products. They are two families, and the families have sub-families that behave differently from each other.
The standard taxonomy, proposed by Dohan Ehrenfest and colleagues in Trends in Biotechnology in 2009 and reaffirmed as consensus for topical and infiltrative use in 2014, sorts every platelet concentrate into four categories on two axes — leukocyte content and fibrin architecture:
| Family | Leukocytes | Fibrin | Physical form |
|---|---|---|---|
| Pure platelet-rich plasma (P-PRP) | Low | Low-density, requires activation | Liquid |
| Leukocyte- and platelet-rich plasma (L-PRP) | High | Low-density, requires activation | Liquid |
| Pure platelet-rich fibrin (P-PRF) | Low | Dense matrix | Solid/gel |
| Leukocyte- and platelet-rich fibrin (L-PRF) | High | Dense matrix | Solid/gel |
Two consequences follow for practice.
First, leukocyte content is a separate variable from fibrin architecture, and it is the one most likely to explain an unexpected inflammatory response. Leukocyte-rich preparations carry neutrophils and monocytes into the treatment site. In musculoskeletal and pain applications that inflammatory contribution is sometimes wanted. In thin facial skin it usually is not.
Second, a brochure that says "PRP" tells you almost nothing. Two kits both labelled PRP can differ in anticoagulant, spin protocol, leukocyte content, activation requirement and final platelet concentration. When you compare your outcomes to a published series, or to a colleague's, you are frequently comparing different materials under the same name. This is the single largest source of noise in the regenerative injectable literature, and it is why so many meta-analyses end with a call for protocol standardisation rather than a recommendation.
If you are building a treatment plan that also involves biostimulators or other regenerative agents, it is worth reading the comparison of exosomes, PDRN and PRP alongside this piece, because the same naming problem affects that category too.
What the biology does not settle
Evidence honesty is part of the job here, and there are three things the mechanism does not deliver.
Mechanistic superiority is not clinical superiority. A more favourable release curve in a 96-well plate is a hypothesis about tissue, not a result in tissue. Several head-to-head clinical comparisons find no significant difference between the two.
Durability is genuinely uncertain for facial applications. A 2025 systematic review of 14 studies of PRP and PRF in periorbital rejuvenation concluded that neither modality is demonstrably superior, and specifically noted that PRF improvements often diminished by six months (Sollitto et al., Journal of Cosmetic Dermatology, 2025). A slower release profile buys days of signalling, not months of result.
Neither product is a volumiser. Whatever a PRF scaffold occupies in the first days, it is a resorbing autologous matrix, not a filler. Volume claims belong to a different category of product entirely, and the distinction between stimulating tissue and replacing it is worth being precise about — the same logic that separates biostimulator injections from fillers applies here, and understanding where facial volume is actually lost will keep you from promising a platelet concentrate can restore it.
What the biology does settle is the constraint set. PRP is liquid, forgiving, spreadable and front-loaded. PRF is viscous, time-limited, structural and sustained. Everything you can and cannot do with each one follows from those four words apiece.
Where this leaves you
The useful mental model is not "which is better." It is: PRP gives you a fast, broad, easily delivered signal with a generous handling window. PRF gives you a slower, localised, scaffold-held signal at the cost of a handling window measured in minutes.
That trade is the real content of the PRP vs PRF decision. The biology described here is what makes the trade real; it does not make the choice for you.
Empire Medical Training's Platelet Rich Plasma Training covers preparation and application of autologous platelet concentrates under supervision, and the Medical Hair Loss, PDO Threads and PRP Hair Restoration workshop covers scalp applications. If your interest is the collagen-stimulation side of the mechanism, our overview of facial collagen stimulation sets the wider context.
Every guide in this cluster
Clinical GuideSingle Spin vs Double Spin PRP: What Actually Changes in the TubeSingle spin vs double spin PRP compared for clinicians — what the second spin concentrates, why volume compensates, and how processing
Clinical GuideLeukocyte-Rich vs Leukocyte-Poor PRP: Matching Cell Content to the IndicationLeukocyte-rich vs leukocyte-poor PRP explained for clinicians — the cytokine data, the PAW, DEPA and Dohan Ehrenfest frameworks, and wh
Clinical GuideDiagnose Before You Treat: The Hair Loss Workup That Must Precede PRPThe hair loss workup before PRP, step by step — onset history, pattern recognition, trichoscopy, category-level labs, and the diagnoses
Clinical GuideSequencing PRP with Microneedling and Laser: Recovery and Remodelling SupportSequencing PRP with microneedling and laser — same-session versus staged delivery, what the recovery evidence supports, and the order o
Clinical GuideScalp Mapping for PRP: Injection Patterns That Guarantee CoverageA PRP scalp injection pattern you can prove — linear front-to-back passes, retrograde technique, circular patterns for defined patches,
Clinical GuideWhy PRP Protocols Fail: Prep Inconsistency, Equipment Drift and the Dehydrated PatientWhy PRP protocols fail before the needle ever reaches the scalp — tourniquet time, anticoagulant ratio, RCF versus RPM, centrifuge drif
Clinical GuideThe Clotting Clock: How the PRF Working Window Reshapes Your RoomThe PRF working window is minutes, not hours. How the clotting clock rewrites room layout, staffing, scheduling and syringe handling in
Clinical GuideChoosing by Clinical Job: A PRP or PRF Decision FrameworkA PRP or PRF decision framework for injectors, organised by the clinical job you need done — release curve, delivery constraint and hon
Clinical GuidePRP with Microneedling: Why PRF Can't Take Its PlacePRP with microneedling works because the material stays liquid, spreads and glides. The materials case for why PRF cannot do that job a
Train with Empire
This guide is clinical education. The technique behind it is taught hands-on, on live patients, with faculty beside you.
Explore PRP & Microneedling Training →Disclaimer
This article reflects the clinical opinions and experience of Tatiana Sarmiento, faculty, Empire Medical Training, an independent faculty member contributing to Empire Medical Training's curriculum. The views expressed are the author's own and do not necessarily represent those of Empire Medical Training.
It is professional education, not medical advice, and is no substitute for hands-on training or independent clinical judgment. Licensed clinicians remain responsible for their own patient selection, technique and outcomes, for verifying current product labelling, and for practising within their scope and applicable law. Empire Medical Training accepts no liability for reliance on this content.